4-Bromo-6-fluoroquinoline

CAS Number 661463-17-8

Chemistry Building Blocks, Fluorinated Building Blocks, Heterocyclic Building Blocks, Materials, Monomers

4-Bromo-6-fluoroquinoline CAS 661463-17-8

A fluorinated quinoline derivative

An intermediate for the preparation of APIs for anti-cancer treatments, dyes for OLEDs and solar cells applications.

Specifications | MSDS | Literature and Reviews

4-Bromo-6-fluoroquinoline (CAS number 661463-17-8) is a dihalogenated quinoline, a benzene-fused pyridine bicyclic heterocycle. Quinoline derivatives are widely used as active pharmaceutical ingredients (APIs). 4-Bromo-6-fluoroquinoline is applied in the synthesis of linrodostat, an inhibitor of indoleamine 2,3-dioxygenase for anti-cancer treatments. The reactivity of 4-bromo-6-fluoroquinoline includes Pd-catalysed coupling reactions on the bromide group and nucleophilic aromatic substitution on the fluoride group.

As an aromatic bicyclic compound, 4-bromo-6-fluoroquinoline can also be used in the preparation of dyes for the applications of OLEDs and solar cells.

Multiple functional groups

For facile synthesis

Fluorinated pyridine building block

For drug discovery, medicinal chemistry and biochemistry research

Worldwide shipping

Quick and reliable shipping

High purity

>98% High purity

General Information

CAS Number	661463-17-8
Chemical Formula	C₉H₅BrFN
Full Name	4-Bromo-6-fluoroquinoline
Molecular Weight	226.05 g/mol
Synonyms	N/A
Classification / Family	Fluorinated building blocks, Heterocyclic building blocks, Quinoline building blocks, APIs, Dyes

Chemical Structure

Product Details

Purity	98%
Melting Point	T_m = 77 °C – 78 °C
Appearance	Off-white powder

MSDS Documentation

4-Bromo-6-fluoroquinoline MSDS Sheet

Literature and Reviews

Rapid development of a commercial process for linrodostat, an indoleamine 2,3-dioxygenase (IDO) inhibitor, K. Fraunhoffer et al., Org. Process Res. Dev., 23(11), 2482–2498(2019), DOI: 10.1021/acs.oprd.9b00359.
Discovery of IACS-9779 and IACS-70465 as potent inhibitors targeting indoleamine 2,3-dioxygenase 1 (IDO1) apoenzyme, M. Hamilton et al., J. Med. Chem., 64(15), 11302–11329(2021); DOI: 10.1021/acs.jmedchem.1c00679.
Preclinical characterization of linrodostat mesylate, a novel, potent, and selective oral indoleamine 2,3-dioxygenase 1 inhibitor, A. Balog et al., Mol. Cancer Ther., 20, 467–476(2021); DOI: 10.1158/1535-7163.MCT-20-0251.

Discovery of orally bioavailable, quinoline-based aldehyde dehydrogenase 1A1 (ALDH1A1) inhibitors with potent cellular activity, S.-M. Yang et al., J. Med. Chem., 61, 4883–4903(2018); DOI: 10.1021/acs.jmedchem.8b00270.